Aligned with our finding of differential splicing in the 5′ untranslated region of CALCA, a single nucleotide polymorphism (rs3781719) located in the promoter region of CALCA has been associated with the response of patients to the OnabotulinumtoxinA chronic migraine therapy [54]. This evidence concerns the gene CALCA and migraine disorder.